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Abstract
Background: Drug-resistant tuberculosis (TB), including resistance to both rifampicin (RIF) and isoniazid (INH)
referred to as multidrug-resistant tuberculosis (MDR-TB), has become an increasing global threat in recent years.
Effective management of patients infected with MDR-TB strains requires identifying such patients by performing
conventional drug-susceptibility testing (DST) on bacteria isolated from sputum, a process that can take up to
2 months. This delay in diagnosis can result in worsening and continued transmission of MDR-TB. Molecular
methods that rely upon nucleic acid amplification of specific alleles known to be associated with resistance to
specific drugs have been helpful in shortening the time to detect drug resistant TB.
Methods: We investigated the utility of the REBA MTB-Rifa®, a commercially available line probe assay (LPA) for
detecting rifampicin (RIF) resistance in the RIF resistance-determining region (RRDR) of the rpoB gene.
Altogether, 492 Mycobacterium tuberculosis (M. tuberculosis) clinical isolates and additional 228 smear- and
culture-positive sputum samples with confirmed M. tuberculosis were collected from subjects with suspected
MDR-TB in South Korea. The results were compared with conventional phenotypic DST and sequencing of
the rpoB gene.
Results: A total of 215 of the 492 isolates were resistant to RIF by conventional DST, and of which 92.1%
(198/215) were MDR-TB strains. The REBA MTB-Rifa® assay identified RIF resistance in 98.1% (211/215) of these
isolates but failed to identify resistance in four phenotypically RIF resistant isolates. These four isolates lacked
mutations in the RRDR but three were confirmed to be MDR-TB strains by sequencing. The sensitivity and
specificity of this test for clinical isolates was thus 98.1% (211/215) and 100% (277/277), respectively. When
applied directly to 228 smear positive sputum samples, the sensitivity and the specificity of REBA MTB-Rifa® assay
was 100% (96/96, 132/132), respectively.
Conclusions: These findings support the use of the REBA MTB-Rifa® assay for rapid detection of RIF resistance
on clinical isolates and smear positive sputum samples. The results also suggest that RIF resistance is a good
surrogate marker of MDR-TB in South Korea and the need to add more probes to other LPAs which can cover
newly identified mutations relevant to RIF resistance.
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Background
Drug-resistant tuberculosis (TB) has become an in-
creasing global threat in recent years. The World Health
Organization has estimated that the global burden of
multidrug-resistant TB (MDR-TB, defined as combined
resistance to INH and RIF) will increase from the
current 500,000 cases per year to nearly 2,000,000 cases
by 2015 [1]. Expanding efforts to treat patients infected
with MDR-TB is leading to the generation of extensively
drug-resistant TB (XDR-TB, defined as MDR-TB plus
resistant to any fluoroquinolone and at least one of
three second-line anti-TB injectable drugs). Treating
patients with MDR-TB requires identifying them by
performing DST on bacteria isolated from sputum, a
process that can take up to 2 months. This delay in
diagnosis can result in worsening of disease and further
transmission of MDR-TB disease.
To avoid this delay in proper diagnosis, several rapid
diagnostic methods have been developed that rely on amp-
lification of specific alleles known to be associated with re-
sistance to specific drugs. LPA, a method that is based on
nucleic acid amplification followed by hybridization of
amplicons to target probes immobilized on membranes to
detect resistance-associated sequence polymorphisms, are
widely used [2]. LPAs have been officially endorsed by the
WHO to detect MDR-TB from cultured isolates and dir-
ectly from smear positive sputum samples [3]. Even though
LPAs, and other molecular techniques are very accurate
and rapid in detecting mutations, they are intrinsically lim-
ited to known mutations in drug targets. For RIF, the diag-
nostic accuracy of detection is quite robust and up to 97%
of isolates can be correctly identified as resistant or suscep-
tible [4]. Although LPAs typically includes both wild type
and mutant alleles, these must be targeted to relatively
short DNA segments that have been demonstrated to be
involved in resistance to specific agents. Newer ways of
detecting RIF resistance alleles, such as the recently intro-
duced GeneXpert MTB/RIF (Cepheid, Sunnyvale, CA) [5]
are also limited by knowledge of the resistance mecha-
nisms involved suggesting detection of new alleles associ-
ated with resistance is therefore an important objective.
The widespread use of RIF in global TB control programs
has inevitably given rise to resistance. The target of RIF is
the β-subunit of the bacterial DNA-dependent RNA poly-
merase, which is encoded by the rpoB gene. In the majority
of the RIF resistant isolates, mutations are found within an
81-bp region known as the RIF resistance determining re-
gion or RRDR. This region encodes 27 amino acids and
corresponds to codons 507 to 533. Mutations within this
region account for up to 95% of the RIF resistance observed
[6-8]. INH has a more complex mode of action and resist-
ance occurs through several discrete mechanisms involving
many genes, therefore detection of INH resistance through
molecular tests is less reliable than RIF [9,10]. RIF
resistance generally occurs in combination with INH and
therefore RIF resistance has been proposed as a surrogate
maker for MDR-TB [11,12]. Despite the simplicity and util-
ity of self-contained diagnostic tests such as the GeneXpert
system, these are twice as expensive as LPAs in a country
like Korea that does not qualify for preferential pricing con-
siderations. Since a large fraction of Korean TB patients are
indigent the price of such testing can place them out of
reach. In addition, reengineering cartridges to take advan-
tage of newly discovered resistance alleles is not trivial [13].
In settings where sufficient technical and microbiological
expertise is not limiting, and self-contained molecular tests
are expensive, LPAs offer an affordable, accurate and flex-
ible alternative.
In this study, we evaluated the utility of reverse blot
assay (REBA MTB-Rifa®) for rapid detection of RIF resist-
ance and assessed its ability to predict RIF resistance for
MDR-TB in South Korea using both M. tuberculosis iso-
lates and clinical specimens in comparison with pheno-
typic DST, and rpoB gene sequencing results.
Methods
Samples
A total of 492M. tuberculosis isolates isolated from sputa
of all consecutive patients with active pulmonary TB at
Masan National Hospital (NMH) in South Korea who
were enrolled in a prospective observational cohort study
(ClinicalTrials.gov identification number, NCT00341601)
between 2005 and 2008 were included in the study. The
study was reviewed and approved by both the NMH
and National Institute of Allergy and Infectious Diseases
(NIAID) institutional ethics review boards and all partici-
pants gave written informed consent. These isolates were
included in the study without regard to their drug suscep-
tibility [14]. Separate from these isolates, 228 recent acid-
fast bacilli positive sputum samples with M. tuberculosis
culture results from routine clinical testing were also in-
cluded (Figure 1).
Clinical isolates and drug susceptibility testing
Sputum specimens obtained from each participant were
processed using sodium hydroxide and N-acetyl-L-cyst-
eine and then screened for acid-fast bacilli using the Ziehl-
Neelsen (ZN) staining method and cultured in Ogawa egg
slants. DST was performed on Lowenstein-Jensen egg
slants containing the relevant anti-TB drugs according to
WHO recommendation [15]. Isolates were tested for re-
sistance to critical concentrations of INH (0.2 μg/mL), RIF
(40 μg/mL), EMB (2.0 μg/mL), PZA (100 μg/mL, Wayne’s
pyrazinamidase assay [16]), ofloxacin (2 μg/mL), and kana-
mycin (40 μg/mL). M. tuberculosis H37Rv (ATCC 27294)
was used as a positive control in all experiments.
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Minimum inhibitory concentration (MIC) determination
A 96-well microtiter plate containing RIF at concentra-
tions ranging from 0.25 μg/mL to 64 μg/mL was used to
test each sample. Colonies were scraped from a 7H10 agar
plate and vortexed in a sterile tube containing 7H9 media
with Tween80 and glass beads. The bacterial suspension
was allowed to stand for 20 min after adjust the suspen-
sion equivalent to McFarland turbidity standard 0.5. From
the supernatant, 100 μL of bacterial suspension was inocu-
lated to each well containing RIF on 96-well plates. Perim-
eter wells on each plate were filled with sterile water to
avoid dehydration of the medium during incubation. A
growth control without RIF and a sterile control without
M. tuberculosis strains were also included for each isolate.
The plates were sealed and incubated at 37°C in 5% CO2
for 7 days. Thereafter 100 uL of Alamar blue (Invitrogen,
Carlsbad, USA) was added, the samples were re-incubated
and read color changes after 24 hrs. Color change from
blue to pink indicated growth of the bacteria, and the
MIC was determined as the lowest drug concentration
that blue color did not turn to pink [17].
Isolation of DNA from clinical MTB isolates
A loopful of bacteria from the Ogawa slant culture was
suspended in 500 μL of distilled water, and incubated for
10 min at 99°C to sterilize bacteria. After centrifugation
for 5 min at 13,000 × g, the supernatant was recovered
and stored at −20°C before use.
DNA preparation from sputum specimens
Sputum specimens were processed using sodium hydrox-
ide and N-acetyl-L-cysteine, and then screened for acid-
fast bacilli with the ZN staining method. Each 500 μL of
decontaminated and processed smear positive sample was
inoculated into liquid culture media (MB/BacT 240). Cul-
tured organisms were sterilized by heating at 99°C for
10 min, and 500 μL was transferred to a microcentrifuge
tube that contained 200 μL of 0.1 mm glass beads (Biospec
products). The tube was processed in a bead-beater
(Biospec products) for 5 min and then centrifuged at
13,000 × g for 5 min. The supernatant were recovered and
stored in −20°C before use.
REBA MTB-Rifa® assay
REBA MTB-Rifa® (YD Diagnostics, Yongin-si, South Korea)
[18] is a commercially available LPA based on the reverse
hybridization principle that specific oligonucleotide probes
are immobilized on a membrane and hybridized under
strictly controlled conditions with the biotin-labeled PCR
product. It consist of 8 probes, of which five probes
representing wild type rpoB sequences that span the RRDR
i.e. 509-514(WT1), 515-520(WT2), 521-525(WT3), 524-
529(WT4) and 530-534(WT5), and three probes [516GAC-
GTC(M1), 531TCG-TTG(M2) and 533CTG-CCG(M3)]
that account for the most common specific mutations. The
assay was performed according to the manufacturer’s in-
struction. Briefly, genomic DNA from each sample was
amplified using two 5′ biotinylated primers with the
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Figure 1 Schema of the study design. *, Number of samples; RIF, rifampicin; RRDR, rifampicin resistance determining region.
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indicated sequences, rpoB 5′long (5′-TCA AGG AGA
AGC GCT ACG ACC TGG C-3′) and TR8 long (5′-ACG
GGT GCA CGT CGC GGA CCT CCA-3′), to get a 536-
bp fragment of rpoB. PCR was carried out for 35 cycles
using ABI 2720 thermal cycler, with each cycle consist of
denaturation at 94°C for 1 min, annealing at 62°C for 30 s,
and primer extension at 72°C for 1 min 30 s, followed by a
final cycle of 10 min at 72°C. For hybridization, 45 μL of
the amplified PCR product was diluted in 105 μL of 2 ×
SSPE-0.1% SDS and heat denatured at 99°C for 10 min.
Denatured DNAs were transferred into parallel channels
according to the manufacturer’s instructions (MN45;
Immunetics, Cambridge, Mass.) perpendicular to the rows
containing oligonucleotide probes and hybridized for
60 min at 50°C. After hybridization, the membrane was
washed twice in 250 mL of 2 × saline-sodium phosphate-
ethylenediaminetetraacetic acid (SSPE)-0.5% sodium dodecyl
sulfate (SDS) buffer at 60°C for 15 min each. The membrane
was incubated in 1:2,000-diluted streptavidin-AP conjugate
(Roche, 11 093 266 910) for 40 min at 42°C. It was followed
by wash twice in 250 mL of 2 × SSPE-0.5% SDS at 42°C, for
10 min each time, and rinsed with 250 mL of 2 × SSPE for
5 min at ambient temperature. Signal was detected by
add sufficient amount of chemiluminescent CDP-Star
(Amersham, RPN3682) to the membrane and incubate
for 5 min, which followed by exposure to X-ray film
(Hyperfilm ECL; Amersham) in accordance with the
manufacturer’s instructions.
PCR amplification and sequencing of the products
Twenty microlitres of each DNA was added to the PCR
mixture. Two primers with the sequences, TR-8 (5′-TGC
ACG TCG CGG ACC TCC A-3′) and TR-9 (5′-TCG
CCG CGA TCA AGG AGT-3′) were used to amplify a
187-bp fragment of the RRDR in rpoB gene. After the re-
action mixtures were incubated at 94°C for 10 min, PCR
was carried out in ABI 2720 thermal cycler for 35 cycles,
with each cycle consisting of denaturation at 94°C for 60 s,
annealing at 62°C for 30 s, and primer extension at 72°C
for 90 s, and a final extension step of 10 min at 72°C. To
confirm the PCR amplification, 5 μL of PCR products
were analyzed in 2% Tris Borate EDTA (TBE) agarose gel
electrophoresis. Direct sequencing of PCR products were
carried out by Genotech (Daejeon, South Korea) and
sequencing results were analyzed using CLC Main
Workbench (CLC bio, Aarhus, Denmark).
Results
Drug susceptibility patterns of MTB isolates
Out of 492 isolates, 200 isolates were pan-susceptible to
all four first line TB drugs (INH, RIF, EMB and PZA)
while the remaining 292 isolates were resistant to one or
more TB drugs. From 292 drug resistant isolates, 215 iso-
lates were RIF resistant, but only 17 samples were RIF
mono-resistant. The remaining 198 (92.1%) isolates were
also resistant to INH and therefore MDR-TB strains. Of
these 198 MDR-TB isolates, 173 (87.4%) showed further
resistance to at least one more first-line drug and 82
(41.4%) isolates were resistant to all tested first line drugs.
Among the new cases, 45 cases were resistant to more
than one drug of which 10 (5.9%) were MDR-TB but not
XDR-TB. Among previously treated cases, 188 (58.4%)
cases were MDR-TB of which 35 (18.6%) cases of XDR-TB
(data not shown).
Detection of Rif resistance using the REBA MTB-Rifa®
assay on DNA from cultured samples
Alterations in the RRDR were detected in 211 isolates
out of 492 samples which tested by REBA MTB-Rifa®
assay. All 211 isolates identified by the REBA MTB-Rifa®
as having mutations in the RRDR were resistant to RIF
by conventional DST testing. However, the REBA MTB-
Rifa® failed to identify four isolates that were phenotypic
RIF-resistant, and the sensitivity and the specificity of
the assay for clinical isolates were 211/215 (98.1%; 95%
CI 95.3, 99.5) and 277/277 (100%; 95% CI 98.7, 100), re-
spectively (Table 1). All of the mutations in the RRDR
observed by REBA MTB-Rifa® assay were confirmed by
DNA sequencing. Of the four phenotypic rifampicin re-
sistant isolates that had no mutations in the RRDR, two
harbored mutations at Val(GTC)-146-Phe(TTC), one
had a mutation at Ile(ATC)-572-Phe(TTC) in the cluster
II region while the fourth isolate was devoid of muta-
tions in either the RRDR or cluster II regions [19,20].
The majority of the mutations (144, 68.2%) were directly
identified by three mutation probes (M1, M2 and M3),
and the detection rate went up to 77.7% (164) if missing
wild type probe signals included. Mutation alone in
codon 531 was detected in 116 (55.0%) isolates by muta-
tion probe and in 122 isolates (57.8%) when missing wild
type probe signals included (Table 2). DNA sequencing
of RRDR showed the mutations in codon 526 were also
common in this isolate collection with 37 isolates show-
ing mutations in that codon (Table 2).
Detection of rifampicin resistance with the REBA MTB-Rifa®
directly on smear positive/culture positive
sputum samples
The REBA MTB-Rifa® assay was applied directly to 228
smear positive sputum samples which were culture posi-
tive, and polymorphisms were detected in 96 of the 228
samples while wild type alleles were identified in the
remaining 132 samples. The REBA MTB-Rifa® assay re-
sults were compared to phenotypic DST results as well
as DNA sequencing of the RRDR of cultured organisms
from the respective sputum samples (Data not shown).
The sensitivity was 96/96 (100%; 95% CI 96.2, 100) and
the specificity was 132/132 (100%; 95% CI 97.2, 100),
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Table 2 rpoB mutations in M. tuberculosis from South Korea
Sequencing REBA MTB-Rifa® assay Sputum Isolates Total
533CTG-CCG 533CTG-CCG, Δ530-534 8 8 16
531TCG-TTG 531TCG-TTG, Δ530-534 59 115 174
531TCG-TGG Δ530-534 1 3 4
531TCG-TGC Δ530-534 1 1 2
531TCG-CAG Δ530-534 0 2 2
526CAC-TAC Δ524-529 4 14 18
526CAC-GAC Δ524-529 4 9 13
526CAC-CTC Δ524-529 2 4 6
526CAC-CCC Δ524-529 1 1 2
526CAC-CGC Δ524-529 1 2 3
526CAC-AAC Δ524-529 0 1 1
526CAC-TGC Δ524-529 0 3 3
526CAC-GGC Δ524-529 0 1 1
526CAC-TCC Δ524-529 0 1 1
522TCG-TGG Δ520-524 0 1 1
518AAC deletion Δ515-520 0 2 2
516GAC-GTC 516GAC-GTC, Δ515-520 6 18 24
516GAC-TAC Δ515-520 3 6 9
516GAC-AAC Δ515-520 0 1 1
513-514 CAA insertion Δ509-514 0 1 1
513-516 deletion Δ509-514, Δ515-520 1 1 2
514TTC-ATC Δ509-514 1 0 1
513CAA-AAA Δ509-514 1 3 4
513CAA-CTA Δ509-514 1 2 3
511CTG-CCG Δ509-514 0 3 3
511CTG-CCG, 516GAC-GGC Δ509-514, Δ515-520 1 0 1
510CAG-CAC, 511CTG-CCG Δ509-514 1 0 1
531TCG-TTG, 516GAC-TAC 531TCG-TTG, Δ530-534, Δ515-520 0 1 1
533CTG-CCG, 516GAC-GGC 533CTG-CCG, Δ530-534, Δ515-520 0 2 2
526CAC-AAC, 516GAC-AAC Δ524-529, Δ515-520 0 1 1
523GGG-GAG, 513CAA-CTA Δ520-524, Δ509-514 0 1 1
518AAC-CAC, 516GAC-GGC Δ515-520 0 1 1
516GAC-GGC, 515ATG-GTG Δ515-520 0 1 1
516GAC-GTC, 513CAA-GAA Δ515-520, Δ509-514 0 1 1
Total 96 211 307
Bold texts are newly identified mutations in this study; Δ, missing wild type probe signal.
Table 1 Rifampicin susceptibilities in correlation with the REBA MTB-Rifa® assay on clinical isolates and sputum samples
Phenotypic DST Sensitivity Specificity
RIF susceptible RIF resistant
Clinical isolates REBA MTB-Rifa® Assay No mutations in RRDR* 277 4 98.1% (211/215) 100% (277/277)
REBA MTB-Rifa® Assay Mutations in RRDR* 0 211
Sputum samples REBA MTB-Rifa® Assay No mutations in RRDR* 132 0 100% (96/96) 100% (132/132)
REBA MTB-Rifa® Assay Mutations in RRDR* 0 96
*RRDR Rifampicin resistance determining regions; RIF Rifampicin; DST Drug susceptibility testing.
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respectively (Table 1). The majority of the mutations
were detected as missing wild type signals (92/96, 95.8%)
and mutation probe could detect specific mutations dir-
ectly in 73 out of 96 (76.0%) sputum samples.
Distribution of rifampicin resistance alleles in the
rpoB protein
Together with isolates and sputum samples, 307 muta-
tions representing 43 different type of mutations in the
RRDR of RpoB protein were identified by sequencing in
this study, which include 10 double mutations, 2 deletions
and a insertion (Table 2). Mutations were located in sev-
eral regions and some of the regions show higher muta-
tion frequencies than other regions (Figure 2). The codon
which most frequently involved in mutations were codon
531 (183, 59.6%), codon 526 (49, 16.0%), codon 516 (42,
13.7%), and codon 533 (18, 5.9%). The most common mu-
tation detected was the Ser(TCG)-531-Leu(TTG), which
was seen in 175 (57.0%) of the 307 RIF resistant strains.
The second most dominant mutation was observed at Asp
(GAC)-516-Val(GTC) (25, 8.1%), followed by His(CAC)-
526-Tyr(TAC) (18, 5.9%) (Figure 1).
In addition, three novel mutations were also identified
in this study. A mutation from Ser(TCG) to Cys(TGC) at
codon 531, a mutation from Phe(TTC) to Ile(ATC) at
codon 514 and insertion of CAA between codons 513 and
514 (MIC 12 μg/mL) to the best our knowledge have not
been reported hitherto.
Discussion
This is the first study to validate the REBA MTB-Rifa® assay
for the rapid detection of RIF resistance. The study used a
large sample size that included both of clinical isolates and
smear-positive/culture positive sputum samples (Figure 1)
(Table 1). It identified all the RIF resistant sputum samples
successfully, and 98.1% (211/215) of all phenotypic RIF re-
sistantM. tuberculosis isolates. The sensitivity for the detec-
tion of RIF resistance for clinical isolates in this study is
slightly higher than in other reports [21,22] and barely
lower than the maximum possible detection rate.
It is worth noting that the 98.1% RIF resistant isolates
and 100% of smear-positive/culture positive sputum sam-
ples with RIF resistance in this study harbored mutations
in the RRDR of the rpoB gene. Several other reports have
shown that about 95% of RIF resistant strains from differ-
ent countries harbor mutations in the RRDR of the rpoB
gene. This assay differs from other LPAs in that it took a
wild type probe [524-529(WT4)] instead of two mutant
probes 526CAC-TAC and 526CAC-GAC, because this
codon is very polymorphic [23], In addition this assay also
employs a 533CTG-CCG mutant probe instead of a wild
type probe, which confers low-level but potentially clinic-
ally important RIF resistance that is often missed by
phenotypic DST.
The distribution of the mutations observed in this study
was generally similar to those reported from other Asian
countries [24]. However, the frequency of Ser-531, Asp-
Figure 2 Representation of the RIF binding site region of RpoB and the 10 sites in which mutations were observed in this study. The
green dotted lines depict hydrogen bonds anchoring the RIF molecule to RpoB. The numbering corresponds to the numbering of the E. coli
protein but the structure corresponds to the RpoB from Thermus aquaticus deposited in PubMed database as 1I6V [32].
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516 and double mutations was higher than in Europe,
Africa, and the United States [25,26], and the mutation
frequency of His-526 was lower than reported in those re-
gions. This suggests that mutational frequency at a specific
genomic location can be different possibly as a conse-
quence of strain-specific genetic differences. However, as
shown in two reports [24,25], racial factors might also re-
sult in different mutation frequencies at specific genomic
locations [27,28]. The unique mutations described in this
study might be due to racial differences, drug regimens
that were taken or treatment compliance of patients as
alluded to above [29-31]. Amongst double mutations,
newly identified Asp(GAC) to Val(GTC) at codon 516 and
Gln(CAA) to Glu(GAA) at codon 513 showed high level
phenotypic RIF resistance (MIC >64 μg/mL).
Even though there were 43 different mutation types iden-
tified in RRDR from 307 RIF resistant samples (211 isolates
and 96 sputum samples), the majority of mutations (292/
307, 95.1%) were located in only 4 codons; 516, 326, 531
and 533 in both the banked isolates and the recent sputum
samples (Table 2). Some mutations were found only in as-
sociation with other mutations (codon 510 CAG-CAC;
codon 513 CAA-CTA; codon 513 CAA-GAA; codon 515
ATG-GTG; codon 516 GAC-GGC; codon 518 AAC-CAC;
codon 523 GGG-GAG) with very low frequency (1–3 sam-
ples). There were 4 RIF resistant isolates without any muta-
tions in the RRDR and sequencing analysis were done to
identify other mutations in the cluster II region of rpoB
gene. Mutation at Val(GTC)-146-Phe(TTC) was observed
in 2 (0.9%) of these isolates, and this mutation was previ-
ously reported in about 1% of RIF resistant isolates, and the
level of RIF resistance in this study was as high as in the
previous report (MIC 8 μg/mL) [20]. We also observed a
mutation at Ile(ATC)-572-Phe(TTC) in an isolate (Figure 1).
The remaining isolate did not have any mutations in either
of RRDR or cluster II region but nonetheless showed high
level of resistance (MIC >64 μg/mL) [19,20]. The failure to
detect mutations in cluster II region of RIF resistant iso-
lates, or the cluster II region by the REBA MTB-Rifa® assay
suggest that incorporation of the respective mutations in
future LPA version would improve the diagnostic accuracy
of such tests.
Nearly all of the observed mutations lie within the RIF
binding site of the RpoB protein, if not within the canonical
RRDR. The two most commonly observed mutations were
Ser-531, which is directly involved in hydrogen bonding to
the napthol ring and His-526 (Figure 2), which may interact
with Asp-516 to form a more extended hydrogen-bonding
interaction. The other observed mutations within the
RRDR have been reported previously and all participate in
direct interaction with various parts of the RIF molecule.
Val-146 lies at the bottom of the pocket and, despite being
far away in primary sequence, is only 5 Å from the napthol
core thereby underscoring its importance. Ile-572 has not
been reported in clinical isolates resistant to RIF but it has
been noted previously that this residue forms part of a
cluster of hydrophobic residues that define one face of the
binding pocket and this residue lies less than 4 Å away
from the naphthalene ring system [32]. Mutation of this
residue to Phe would therefore very likely sterically pre-
clude RIF binding. These results suggest that to achieve
100% coverage of all possible RIF resistance-conferring
mutations it may be necessary to include up to a total of
10 additional alleles based upon the RIF binding site.
The majority of the RIF resistant isolates and clinical
samples in this study were also MDR-TB suggesting that
RIF resistance may not only be a suitable surrogate
marker of MDR-TB in high TB incidence settings as sug-
gested by the WHO but in medium TB incidence set-
tings like South Korea as well. A limitation of this study
is that the REBA MTB-Rifa® assay was not applied to
sputum smear negative cases. This is primarily because
our recruitment site predominantly treats confirmed TB
cases in smear positive patients. The samples used in
this study, therefore may not be representative of the en-
tire South Korean TB population but are a fair represen-
tation of the difficult-to-treat TB cases being seen in the
national reference hospitals.
Conclusions
The findings reported herein support the utility of the
REBA MTB-Rifa® assay as an alternative tool for the
reliable rapid detection of RIF resistance on clinical
isolates and smear positive sputum samples in South
Korea, and likely in the entire Korean peninsula and
surrounding regions as well. Since most (92.1%) of RIF
resistant strains in this study were also resistant to
INH, the results suggest that RIF resistance may also
be a suitable surrogate marker of MDR-TB in a setting
of moderate TB incidence such as Korea.
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